TABLE 2.
Second-Line Therapy Utilization Inputs
| Second-Line Treatment Mix, % | Initial Empiric Therapy | Reference Source | |||
| Vanc | Lin | Dap | Ori | ||
| Inpatient: Switch due to AE or nonresponse | |||||
| Vancomycin IV | 0.0 | 74.0 | 93.0 | 68.0 | 20, 25 |
| Linezolid IV | 22.0 | 0.0 | 7.0 | 20.0 | 20, 25 |
| Daptomycin IV | 78.0 | 26.0 | 0.0 | 12.0 | 20, 25 |
| Oritavancin IV | 0.0 | 0.0 | 0.0 | 0.0 | Expert opiniona |
| Inpatient: De-escalation of therapy | |||||
| Linezolid PO | 14.0 | 73.0 | 28.0 | 0.0 | 20, 25 |
| Oritavancin IV | 0.0 | 0.0 | 0.0 | 0.0 | Expert opiniona |
| Daptomycin IV | 0.0 | 0.0 | 0.0 | 0.0 | 20, 25 |
| Trimethoprim-sulfamethoxazole PO | 40.0 | 13.0 | 36.0 | 0.0 | 20, 25 |
| Doxycycline PO | 23.0 | 12.0 | 12.0 | 0.0 | 20, 25 |
| Clindamycin PO | 23.0 | 2.0 | 24.0 | 0.0 | 20, 25 |
| Outpatient: Switch due to AE or nonresponse | |||||
| Vancomycin IV | 0.0 | 74.0 | 93.0 | 68.0 | 20, 25 |
| Linezolid IV | 22.0 | 0.0 | 7.0 | 20.0 | 20, 25 |
| Daptomycin IV | 78.0 | 26.0 | 0.0 | 12.0 | 20, 25 |
| Outpatient: De-escalation of therapy | |||||
| Linezolid PO | 14.0 | 73.0 | 28.0 | 0.0 | 20, 25 |
| Trimethoprim-sulfamethoxazole PO | 40.0 | 13.0 | 36.0 | 0.0 | 20, 25 |
| Doxycycline PO | 23.0 | 12.0 | 12.0 | 0.0 | 20, 25 |
| Clindamycin PO | 23.0 | 2.0 | 24.0 | 0.0 | 20, 25 |
aExpert opinion from authors Dufour, Nicolau, and Lodise.
AE = adverse event; Dap = daptomycin; IV = intravenous; Lin = linezolid; Ori = oritavancin; PO = oral therapy; Vanc = vancomycin.